camptothecin has been researched along with urea in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Jelic, S; Nikolic-Tomasevic, Z; Popov, I; Radosavljevic, D | 1 |
| Chen, Z; Gu, W; Kovar, P; Li, G; Lin, NH; Mantei, RA; Rosenberg, SH; Sham, HL; Sowin, T; Wang, GT; Xiao, Z; Zhang, H | 1 |
| Bui, MH; Chen, Z; Gu, WZ; Kovar, P; Li, G; Lin, NH; Rosenberg, SH; Sham, HL; Sowin, TJ; Tao, ZF; Tong, Y; Wang, G; Wang, JY; Xiao, Z; Xue, J; Zhang, H | 1 |
| Bui, MH; Chen, Z; Gu, W; Johnson, E; Judge, R; Kovar, P; Lin, NH; Merta, P; Park, C; Rosenberg, S; Sowin, T; Stewart, KD; Tao, ZF; Wang, L; Zhang, H | 1 |
| Darro, F; Dewelle, J; Dumont, P; El Yazidi, M; Gaussin, JF; Kiss, R; Lefranc, F; Mahieu, T; Mijatovic, T; Ribaucour, F; Sauvage, S; Simon, G; Tuti, J; Van Quaquebeke, E; Van Vynckt, F | 1 |
| Ashwell, S; Brassil, PJ; Dai, J; Garner, CE; Gönen, M; Goteti, K; Kern, SE; Moustakas, DT; Schwartz, GK; Utley, L; Zabludoff, S | 1 |
| Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT | 1 |
| Almeida, L; Ashwell, S; Brassil, P; Breed, J; Deng, C; Gero, T; Grondine, M; Horn, C; Ioannidis, S; Janetka, J; Liu, D; Lyne, P; Newcombe, N; Oza, V; Pass, M; Read, J; Ready, S; Rowsell, S; Su, M; Toader, D; Vasbinder, M; Xue, Y; Yu, D; Yu, Y; Zabludoff, S | 1 |
| Furukori, K; Nagasawa, K; Odagi, M; Watanabe, T | 1 |
| Chen, Y; Gao, JM; Lee, KH; Li, B; Li, H; Liu, YQ; Morris-Natschke, SL; Song, ZL; Wang, MJ; Xu, C; Yang, CJ; Zhang, ZJ; Zhao, XB | 1 |
1 trial(s) available for camptothecin and urea
| Article | Year |
|---|---|
Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Colorectal Neoplasms; Creatinine; Diarrhea; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Risk Factors; Urea | 2000 |
10 other study(ies) available for camptothecin and urea
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; Checkpoint Kinase 1; Crystallography, X-Ray; Doxorubicin; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Structure-Activity Relationship; Urea | 2005 |
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Topics: Antibodies; Blotting, Western; Camptothecin; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; HeLa Cells; Humans; Molecular Structure; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Time Factors; Tumor Suppressor Protein p53; Urea | 2006 |
Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; Crystallography, X-Ray; DNA Damage; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Macrocyclic Compounds; Models, Molecular; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship; Urea | 2007 |
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Topics: Acetamides; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Deoxycytidine; Drug Screening Assays, Antitumor; Erythrocyte Count; Female; Gemcitabine; Humans; Imides; Irinotecan; Isoquinolines; Leukocyte Count; Maximum Tolerated Dose; Mice; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Platelet Count; Structure-Activity Relationship; Topoisomerase I Inhibitors; Urea | 2007 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Flavonoids; Genes, cdc; Growth Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Piperidines; Predictive Value of Tests; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Topics: Animals; Antineoplastic Agents; Binding Sites; Camptothecin; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; DNA Damage; Drug Design; Drug Synergism; Gemcitabine; High-Throughput Screening Assays; Irinotecan; Mice; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2012 |
Asymmetric α-hydroxylation of a lactone with vinylogous pyridone by using a guanidine-urea bifunctional organocatalyst: catalytic enantioselective synthesis of a key intermediate for (20S)-camptothecin analogues.
Topics: Camptothecin; Guanidines; Hydroxylation; Indolizines; Lactones; Oxidation-Reduction; Pyridones; Pyrones; Stereoisomerism; Structure-Activity Relationship; Urea | 2014 |
Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Urea | 2020 |